Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial

International Journal of Stroke : Official Journal of the International Stroke Society
Sang Won HanMAESTRO Study Investigators

Abstract

The antiplatelet effect of clopidogrel is reportedly influenced by cytochrome P450 2C19 (CYP2C19) polymorphisms. However, there is no data concerning the relationship between stroke recurrence and CYP2C19 polymorphisms in patients treated with clopidogrel for secondary prevention of ischemic stroke. Triflusal may be an alternative therapy for clopidogrel in patients with poor genotype. The Comparison of Triflusal and Clopidogrel Effects in Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping (MAESTRO) study will investigate the effect of antiplatelet agents based on CYP2C19 polymorphisms in secondary prevention of ischemic stroke. Assuming that 55% of patients belong to the poor genotype group, the required sample size is 1080 patients with at least 24 months of follow-up. This study is designed as a prospective, multicenter, randomized, parallel-group, open-label, and blind genotype trial. Patients who experience their first non-cardiogenic ischemic stroke within 30 days prior to screening are eligible. Patients received 300 mg triflusal twice a day or 75 mg clopidogrel once daily during the trial. The study is registered with ClinicalTrials.gov (NCT01174693). The primary outcome is recurrent ischemic stroke...Continue Reading

References

Apr 14, 2004·Neurology·A CulebrasUNKNOWN TAPIRSS investigators
Aug 19, 2008·International Journal of Stroke : Official Journal of the International Stroke Society·Andrei V Alexandrov, Peter Alagona
Aug 30, 2008·The New England Journal of Medicine·Ralph L SaccoUNKNOWN PRoFESS Study Group
Dec 25, 2008·The New England Journal of Medicine·Tabassome SimonUNKNOWN French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators
Dec 25, 2008·The New England Journal of Medicine·Jessica L MegaMarc S Sabatine
Oct 29, 2010·The New England Journal of Medicine·Guillaume ParéJohn W Eikelboom
Nov 5, 2010·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Michal KralPetr Kanovsky
Mar 14, 2012·Nature Reviews. Neurology·Bruce A WardenCraig D Williams
May 18, 2012·The New England Journal of Medicine·Stephen M Davis, Geoffrey A Donnan
Sep 28, 2012·International Journal of Stroke : Official Journal of the International Stroke Society·J A KinsellaD J H McCabe
Apr 13, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vincent Lai Ming Yip, Munir Pirmohamed
Jul 16, 2013·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Ilana SpokoynyDavid Tong
Jul 26, 2013·Thrombosis and Haemostasis·Jolanta M Siller-Matula, Bernd Jilma
May 3, 2014·Stroke; a Journal of Cerebral Circulation·Walter N KernanUNKNOWN American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and
Aug 29, 2014·Current Pharmaceutical Design·Anjana Munshi, Vandana Sharma
May 29, 2015·Journal of the American Heart Association·Caitrin W McDonoughAlan R Shuldiner
Aug 13, 2015·European Journal of Clinical Pharmacology·Jean-Philippe ColletUNKNOWN ARCTIC investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
Genotyping

Clinical Trials Mentioned

NCT01174693

Software Mentioned

MAESTRO
Real

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.